Skip to content
The Nexus
DossierENTITY

Lyn Baranowski

Coverage of Lyn Baranowski in the Nexus archive.

Earliest in view: Apr 30 · 16:36 UTCMost recent: Apr 30 · 16:36 UTC
Co-mentioned in this coverage
Avalyn Pharma Inc.organization1Novoorganization1Nasdaq MarketSiteplace1New Yorkplace1USplace1biopharmatopic1rare lung diseasestopic1
Recent coverage
  • BUSINESSApr 30 · 16:36 UTCBLOOMBERG
    Novo-Backed Drugmaker Avalyn Soars 44% After $300 Million US IPO

    Avalyn Pharma Inc., a biopharma company developing inhaled treatments for rare lung diseases, raised $300 million in a US initial public offering that priced at the top of its marketed range. The stock surged 44% on its first day of trading, with CEO Lyn Baranowski ringing the opening bell at Nasdaq MarketSite in New York.

Lyn Baranowski · Dossier · The Nexus